PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Phase I clinical trial shows drug shrinks melanoma brain metastases

3-pronged study reveals high response rate in other advanced melanoma patients and activity in multiple cancers

2012-05-18
(Press-News.org) HOUSTON – An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

The drug dabrafenib, which targets the Val600 BRAF mutation that is active in half of melanoma cases, also cut the size of tumors in 25 of 36 patients with late-stage melanoma that had not spread to the brain. The drug also showed activity in other cancer types with the BRAF mutation.

"Nine out of 10 responses among patients with brain metastases is really exciting. No other systemic therapy has ever demonstrated this much activity against melanoma brain metastases," said study co-lead author Gerald Falchook, M.D., assistant professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Melanoma patients whose disease has spread to their brains have a median overall survival of four or five months, the researchers noted. Drugs used to treat brain metastases have response rates of 10 percent or lower. Surgery and stereotactic or whole-brain radiation also are used.

Tumor shrinkage in the nine responders ranged from 20 percent to 100 percent. In four cases, the brain metastases disappeared.

Drug's reach into brain a surprise

These results will need to be validated in additional clinical trials with larger groups of patients, Falchook said. "This changes how we think of this drug and exclusion criteria for future trials."

"Most clinical trials exclude patients with brain metastases because the drugs are assumed not to cross the blood-brain barrier," Falchook said. "These are the patients most in need of a clinical trial because their treatment options are so limited."

Dabrafenib, made by GlaxoSmithKline, was not designed to cross the blood-brain barrier, which protects the brain from toxic substances in the blood.

The drug's activity against brain metastases was initially a serendipitous finding at one study site. In one patient, a research PET scan performed just before starting dabrafenib revealed a brain metastasis, but this result was not available until after treatment began. The institution's ethics board approved the patient to continue treatment because a follow-up PET scan two weeks later showed decreased metabolic activity in the brain metastasis and subsequent MRIs showed a reduction in its size.

The team then designed a sub-study for 10 patients with untreated brain metastases, Falchook said. The mechanism by which dabrafenib reaches tumors in the brain is under investigation.

"In all of these patients with melanoma brain metastases, the tumors eventually progressed," Falchook said. Prevention of drug resistance remains a challenge in advanced cancers.

High response rate for those without brain metastases

184 patients enrolled at eight sites in the United States and Australia. Of these, 156 patients had melanoma that had spread to other organs. MD Anderson enrolled 64 patients.

The main purpose of a phase I clinical trial is to gradually escalate an experimental drug's dosage to evaluate side effects and establish the highest possible dose that can be safely given.

The researchers never reached a maximum-tolerated dose limit. No patients had to discontinue the drug due to side effects, and few patients experienced severe toxicity. "This is a very non-toxic drug, which is common with these newer, targeted therapies," Falchook said.

Based on response rates and the drug's pharmacokinetics – how the body metabolizes it – the team recommended an oral dose of 150 mg twice daily for future phase II and phase III trials. In the second stage of the phase I trial, they tested that dose in:

36 patients with melanoma with the Val600 BRAF mutation without brain metastases, 10 patients with untreated melanoma brain metastases, and 28 patients with other BRAF-mutant cancers.

Among the 36 melanoma patients without untreated brain metastases:

25 (69 percent) had a partial or complete response, which is shrinkage of at least 30 percent as determined by measuring tumor shrinkage with radiographic imaging, 18 (50 percent) had a confirmed response, meaning the reduction in size was observed in a second imaging scan at least one month later, 17 (47 percent) stayed on the trial for more than six months, and. Responses were seen in the less common Val600Lys BRAF mutation.

The confirmed response rate was similar to that in a phase III study of vemurafenib, the first drug approved for treatment of BRAF-mutant melanoma.

Among those with other types of cancers, patients with papillary thyroid, non-small cell lung and colorectal cancers had partial responses.

"This is further evidence that a tumor's molecular profile is as important, and possibly more important, than the organ where the cancer begins," Falchook said.

"We need to screen for BRAF and other molecular abnormalities in our patients' tumors," he said. "In many other tumor types BRAF mutations occur in small percentages of patients. If we're not testing for it routinely, these patients might never be treated with a promising targeted agent for their cancer."

Falchook has six melanoma patients still receiving dabrafenib, including five who are in complete remission. In addition, Falchook is still treating six papillary thyroid patients and one colorectal cancer patient whose tumors have not progressed on the treatment.

INFORMATION:

GlaxoSmithKline sponsored and funded the clinical trial. Phase II and phase III trials of dabrafenib for melanoma are under way.

Co-authors with Falchook are Razelle Kurzrock, M.D., of MD Anderson's Department of Investigational Cancer Therapeutics, and Kevin Kim, M.D. of MD Anderson's Department of Melanoma Medical Oncology; co-lead author Georgina Long, M.D., Ph.D., and senior author Richard Kefford, M.D., Ph.D., of Melanoma Institute Australia, Westmead Institute for Cancer Research and Westmead Hospital, University of Sydney, in Sydney, Australia; Tobias Arkenau, M.D., Ph.D., Prince of Wales Hospital, Randwick, Australia; Michael Brown, M.D., Ph.D., Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia; Omid Hamid, M.D., and Steven O'Day, M.D., of The Angeles Clinic and Research Institute. Los Angeles, Calif.; Jeffrey Infante, M.D., Sarah Cannon Research Institute, Nashville, Tenn.; Michael Millward, M.D., Cancer Council of Western Australia, Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia; Anna Pavlick, M.D., New York University School of Medicine; and Samuel Blackman, M.D., Ph.D., C. Martin Curtis, Peter Lebowitz, M.D., Ph.D., Bo Ma, Ph.D., and Daniele Ouellet, Ph.D., of GlaxoSmithKline Research and Development, Philadelphia.

END



ELSE PRESS RELEASES FROM THIS DATE:

Ohio's Only Life-Size Wax Museum Celebrates 25 Years with 25-Cent Tours

Ohios Only Life-Size Wax Museum Celebrates 25 Years with 25-Cent Tours
2012-05-18
The world's largest religious wax museum turns 25 this year. To honor the anniversary, BibleWalk, the Living Bible Museum located in Mansfield, Ohio is offering the tours for just 25 cents during its birthday week, Aug. 12-17. The museum offers four different tours, a collection of rare Bibles and the world's largest collection of American votive folk-art. This unique art form became stylish in the 1910s among newly arrived immigrants who would collect costume jewelry, hat and tie pins, beads, cuff links, collar studs, coins, and other items, sculpting them into elaborate ...

Prosthetic retina offers simple solution to restoring sight

2012-05-18
A device which could restore sight to patients with one of the most common causes of blindness in the developed world is being developed in an international partnership. Researchers from the University of Strathclyde and Stanford University in California are creating a prosthetic retina for patients of age related macular degeneration (AMD), which affects one in 500 patients aged between 55 and 64 and one in eight aged over 85. The device would be simpler in design and operation than existing models. It acts by electrically stimulating neurons in the retina, which ...

Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers

2012-05-18
AURORA, Colo. (May 17, 2012) - We have known for years that when the proteins RalA and RalB are present, cells in dishes copy toward aggressive forms of cancer. However, until this week, no study had explored the effects of RAL proteins in human cancers – an essential step on the path to developing drugs to target these proteins. From metastasis in bladder cancer, to seminal vessel involvement in prostate cancer, to shortened survival in squamous cell carcinoma, a study published this week in the journal Cancer Research shows that proteins RalA and RalB are associated with ...

NPS professor publishes article in the AAAS journal Science

NPS professor publishes article in the AAAS journal Science
2012-05-18
(Monterey, CA) – The work of Naval Postgraduate School (NPS) Operations Research Professor Moshe Kress will be featured in the upcoming edition of the American Association for the Advancement of Science's Science Journal, a leading scientific research and news publication. Kress' article, titled "Modeling Armed Conflicts," reviews quantitative approaches to modeling military operations, threat situations, and force structure. The piece reviews historical, classical, present and future armed conflict models, including the dynamics of today's insurgencies. Kress has ...

Stratos Jet Charters Can Take You to the 2012 Summer Games in London in Luxury and Convenience

2012-05-18
The excitement for the 2012 Olympic Summer Games in London, England is starting to build. And though Beijing's impressive $100 million-plus opening ceremonies for the 2008 Olympics will be hard to top, London is certainly going to try. In December, Prime Minister David Cameron doubled the budget for the opening and closing ceremonies to $130 million (81 million pounds) and new casting calls went out almost immediately. Danny Boyle (of Slumdog Millionaire fame) is choreographing the event and is promising 12,000 performers, including dancers, drummers, acrobats, skateboarders, ...

Babies' susceptibility to colds linked to immune response at birth

2012-05-18
Innate differences in immunity can be detected at birth, according to new research at Washington University School of Medicine in St. Louis. And babies with a better innate response to viruses have fewer respiratory illnesses in the first year of life. "Viral respiratory infections are common during childhood," says first author Kaharu Sumino, MD, assistant professor of medicine. "Usually they are mild, but there's a wide range of responses — from regular cold symptoms to severe lung infections and even, in rare instances, death. We wanted to look at whether the innate ...

Herschel Space Observatory study reveals galaxy-packed filament

2012-05-18
A McGill-led research team using the Herschel Space Observatory has discovered a giant, galaxy-packed filament ablaze with billions of new stars. The filament connects two clusters of galaxies that, along with a third cluster, will smash together and give rise to one of the largest galaxy superclusters in the universe. The filament is the first structure of its kind spied in a critical era of cosmic buildup when colossal collections of galaxies called superclusters began to take shape. The glowing galactic bridge offers astronomers a unique opportunity to explore ...

Dangerous Brand Names: Posing a Threat to You and Your Family?

2012-05-18
Harmful ingredients masked in product labels affect the unaware The National Skin Care Institute wants to warn consumers of the risk toxic products poise to their skin and overall general health. There is not enough transparency being seen from big brand names and consumers are often unaware of the harmful chemical ingredients contained in the products they are bringing into their homes and exposing their families to. The worst part is that many of these products are being marketed as safe for use on the smallest and most vulnerable of us all - babies. Big brand name ...

IU research: Forest diversity from Canada to the sub-tropics influenced by family proximity

IU research: Forest diversity from Canada to the sub-tropics influenced by family proximity
2012-05-18
BLOOMINGTON, Ind. -- How species diversity is maintained is a fundamental question in biology. In a new study, a team of Indiana University biologists has shown for the first time that diversity is influenced on a spatial scale of unparalleled scope, in part, by how well tree seedlings survive under their own parents. Scientists have long considered conspecific negative density dependence (CNDD), a process where the mortality of a species rises in coincidence with its increasing abundance, to be a key mechanism maintaining diversity at the local scale. In new research ...

Danuser Wobble Auger - 800-733-0275 - Made in the USA

2012-05-18
Hamilton Equipment - 800-733-0275 - is proud to introduce the new Danuser Wobble Auger, in addition to the full line of stocking Danuser wholegoods and parts. The Wobble Auger is called the "Dirtless Digging Solution" because it quickly produces a hole with no loose dirt in the bottom - or around the top of the hole! The spiral and checkered hardfacing pushes through dirt, frozen ground, sand, clay, asphalt, compacted rock and embedded rock. See our video, above, to watch the Wobble Auger work in packed dirt and frozen ground!! There are various collar ...

LAST 30 PRESS RELEASES:

Exercise as an anti-ageing intervention to avoid detrimental impact of mental fatigue

UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’

New guidelines aim to improve cystic fibrosis screening

Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas

Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition

CCNY physicists uncover electronic interactions mediated via spin waves

Researchers’ 3D-printing formula may transform future of foam

Nurture more important than nature for robotic hand

Drug-delivering aptamers target leukemia stem cells for one-two knockout punch

New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed

New sea grant report helps great lakes fish farmers navigate aquaculture regulations

Strain “trick” improves perovskite solar cells’ efficiency

How GPS helps older drivers stay on the roads

Estrogen and progesterone stimulate the body to make opioids

Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation

Machine learning helps construct an evolutionary timeline of bacteria

Cellular regulator of mRNA vaccine revealed... offering new therapeutic options

Animal behavioral diversity at risk in the face of declining biodiversity

Finding their way: GPS ignites independence in older adult drivers

Antibiotic resistance among key bacterial species plateaus over time

‘Some insects are declining but what’s happening to the other 99%?’

Powerful new software platform could reshape biomedical research by making data analysis more accessible

Revealing capillaries and cells in living organs with ultrasound

American College of Physicians awards $260,000 in grants to address equity challenges in obesity care

Researchers from MARE ULisboa discover that the European catfish, an invasive species in Portugal, has a prolonged breeding season, enhancing its invasive potential

Rakesh K. Jain, PhD, FAACR, honored with the 2025 AACR Award for Lifetime Achievement in Cancer Research

Solar cells made of moon dust could power future space exploration

Deporting immigrants may further shrink the health care workforce

Border region emergency medical services in migrant emergency care

Resident physician intentions regarding unionization

[Press-News.org] Phase I clinical trial shows drug shrinks melanoma brain metastases
3-pronged study reveals high response rate in other advanced melanoma patients and activity in multiple cancers